Previous 10 | Next 10 |
Biotechvalley Insights is upgrading ALT's rating to "Very Bullish" from a "Bullish" rating with a 12 month TP of US$52. Altimmune's (ALT) valuation is at a discount after the recent sell-off, and the fundamental picture has improved with more clarity around manufacturing. ALT has ...
Greenwich LifeSciences (GLSI) +4.8% PM, will virtually ring the Nasdaq opening bell on Dec.28, 2020 for recently completing its IPO."We are developing our GP2 immunotherapy to prevent breast cancer recurrences. With the IPO and follow-on offering, we have now raised over $33M, and a...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that it will ...
Shares of GLSI are up nearly 600% over the past month with market enthusiasm over phase 2b trial data for its 'GP2' breast cancer immunotherapy. GP2 may be able to reduce breast cancer recurrence rate to 0% over 5-years, representing a significant clinical advantage to alternatives on...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the closing o...
Shares of Greenwich LifeSciences (NASDAQ: GLSI) were down by 13.5% as of 2:41 p.m. EST on Friday following its announcement of the pricing of a public offering of common stock. Naturally, investors aren't excited with the prospect of the clinical-stage biopharmaceutical company dilu...
Gainers: CURO Group (CURO) +78%.Mereo BioPharma (MREO) +49%.Cyclo Therapeutics (CYTH) +42%.China Green Agriculture (CGA) +30%.Origin Agritech (SEED) +23%.Upstart (UPST) +22%.AgEagle Aerial Systems (UAVS) +22%.Elys Game Technology (ELYS) +22%.Organovo (ONVO) +21%.Aqua Metals (AQMS) +...
Gainers: Mereo BioPharma (MREO) +91%, Cyclo Therapeutics (CYTH) +44%, Petros Pharmaceuticals (PTPI) +29%, CNS Pharmaceuticals (CNSP) +17%, Humanigen (HGEN) +17%.Losers: Mesoblast (MESO) -34%, Virios Therapeutics (VIRI) -30%, BioCardia (BCDA) -...
Mesoblast (MESO) -31% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19.Wunong Net Technology Company (WNW) -18%.Applied DNA Sciences (APDN) -16% on Q4 earnings release.Takung Art (TKAT) -14%.Virgin Galactic Holdings (SPCE) -11%&...
Greenwich LifeSciences (GLSI) down 12.4% premarket on pricing upsized offering of 660K shares at $40/share, for gross proceeds of ~$26.4M (or ~$30.4M, if underwriters exercise their option in full).Underwriters' over-allotment is an additional 99K shares. Net proceeds will...
News, Short Squeeze, Breakout and More Instantly...
Greenwich LifeSciences Inc. Company Name:
GLSI Stock Symbol:
NASDAQ Market:
Greenwich LifeSciences Inc. Website:
2024-07-11 21:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, tod...
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer r...